ReviewCancer informatics2015
Integrative analyses of cancer data: a review from a statistical perspective.
Review in Cancer informatics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- An integrated transcriptomics and metabolomics study of the immune response of newly hatched chicks to the cytosine-phosphate-guanine oligonucleotide stimulation.Poultry science · 2020Article
- Integrative analysis reveals disrupted pathways regulated by microRNAs in cancer.Nucleic acids research · 2018Article
- Prediction With Dimension Reduction of Multiple Molecular Data Sources for Patient Survival.Cancer informatics · 2017Article
- Discovering MicroRNA-Regulatory Modules in Multi-Dimensional Cancer Genomic Data: A Survey of Computational Methods.Cancer informatics · 2016Review
- Integrating heterogeneous genomic data to accurately identify disease subtypes.BMC medical genomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has become increasingly common for large-scale public data repositories and clinical settings to have multiple types of data, including high-dimensional genomics, epigenomics, and proteomics data as well as survival data, measured simultaneously for the same group of biological samples, which provides unprecedented opportunities to understand cancer mechanisms from a more comprehensive scope and to develop new cancer therapies. Nevertheless, how to interpret a wealth of data into biologically and clinically meaningful information remains very challenging. In this paper, I review recent development in statistics for integrative analyses of cancer data. Topics will cover meta-analysis of homogeneous type of data across multiple studies, integrating multiple heterogeneous genomic data types, survival analysis with high-or ultrahigh-dimensional genomic profiles, and cross-data-type prediction where both predictors and responses are high-or ultrahigh-dimensional vectors. I compare existing statistical methods and comment on potential future research problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.